Leerink Partners Sticks to Its Buy Rating for Neurogene (NGNE)

TipRanksJul 26 13:59 · Ratings

Neurogene to Participate in BMO Genetic Medicines Summit

BusinesswireJul 2 19:30

Neurogene Announces Addition to Russell 3000 Index

BusinesswireJul 1 19:30

Express News | Neurogene Inc : BMO Initiates Coverage With Outperform Rating; Target Price $65

BreakingsJun 27 18:44

Neurogene Price Target Announced at $65.00/Share by BMO Capital

Dow JonesJun 27 17:27

Neurogene Initiated at Outperform by BMO Capital

Dow JonesJun 27 17:27